ASH DLBCL   |  December 16, 2019   John M. Pagel, MD, PhD, on Polatuzumab Vedotin John M. Pagel, MD, PhD, from the Swedish Cancer Center, discussed the recent approval of polatuzumab vedotin in combination with bendamustine plus rituximab in patients with relapsed diffuse large B-cell lymphoma. Read more   ADVERTISEMENT   Andre H. Goy, MD, MS, Discusses Extending Survival for Patients with DLBCL Andre H. Goy, MD, MS, chairman of John Theurer Cancer Center, from Hackensack University Medical Center, discussed ways to address the challenge of extending survival for patients with diffused large B-cell lymphoma who achieved a complete remission. Read more